{"_links": {"parentPackage": {"href": "/mdr/ct/packages/sdtmct-2023-06-30", "title": "SDTM Controlled Terminology Package 54 Effective 2023-06-30", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/sdtmct-2023-03-31/codelists/C66738", "title": "CDISC SDTM Trial Summary Parameter Short Name Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/sdtmct/codelists/C66738", "title": "Version-agnostic anchor resource for codelist C66738", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/sdtmct-2023-06-30/codelists/C66738", "title": "CDISC SDTM Trial Summary Parameter Short Name Terminology", "type": "Code List"}}, "conceptId": "C66738", "definition": "The test code for an individual characteristic of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial.", "extensible": "true", "name": "Trial Summary Parameter Test Code", "preferredTerm": "CDISC SDTM Trial Summary Parameter Short Name Terminology", "submissionValue": "TSPARMCD", "synonyms": ["Trial Summary Parameter Test Code"], "terms": [{"conceptId": "C98703", "definition": "Actual number of subjects enrolled; may include subjects who were not randomized.", "preferredTerm": "Actual Subject Number", "submissionValue": "ACTSUB", "synonyms": ["Actual Number of Subjects"]}, {"conceptId": "C146995", "definition": "Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study.", "preferredTerm": "Adaptive Study Design Indicator", "submissionValue": "ADAPT", "synonyms": ["Adaptive Design"]}, {"conceptId": "C49703", "definition": "The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products.", "preferredTerm": "Test Product Added to Existing Treatment", "submissionValue": "ADDON", "synonyms": ["Added on to Existing Treatments"]}, {"conceptId": "C49694", "definition": "The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Maximum Age of Subjects", "submissionValue": "AGEMAX", "synonyms": ["Planned Maximum Age of Subjects"]}, {"conceptId": "C49693", "definition": "The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Minimum Age of Subjects", "submissionValue": "AGEMIN", "synonyms": ["Planned Minimum Age of Subjects"]}, {"conceptId": "C126058", "definition": "A textual description as to whether a biospecimen is retained and/or contains DNA.", "preferredTerm": "Biospecimen Retained and/or Contains DNA Indicator", "submissionValue": "BIOSPRET", "synonyms": ["Biospecimen Retention Contains DNA"]}, {"conceptId": "C127788", "definition": "A bibliographical reference related to a particular study.", "preferredTerm": "Clinical Study Citation", "submissionValue": "CITNSTDY", "synonyms": ["Citation Used in Study"]}, {"conceptId": "C127789", "definition": "The state or condition of the sponsor as pertains to whether the sponsor is considered a commercial entity.", "preferredTerm": "Sponsor Commercial Status", "submissionValue": "CMSPSTAT", "synonyms": ["Commercial Sponsor Status"]}, {"conceptId": "C68612", "definition": "A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial.", "preferredTerm": "Active Comparator Drug", "submissionValue": "COMPTRT", "synonyms": ["Comparative Treatment Name"]}, {"conceptId": "C176375", "definition": "E-mail address of study contact.", "preferredTerm": "Study Contact E-mail Address", "submissionValue": "CONEMAIL", "synonyms": ["Contact E-Mail Address"]}, {"conceptId": "C176376", "definition": "Mailing address of study contact.", "preferredTerm": "Study Contact Postal Address", "submissionValue": "CONMAIL", "synonyms": ["Contact Mailing Address"]}, {"conceptId": "C176373", "definition": "Name of study contact.", "preferredTerm": "Study Contact Name", "submissionValue": "CONNAME", "synonyms": ["Contact Name"]}, {"conceptId": "C176374", "definition": "Phone number of study contact.", "preferredTerm": "Study Contact Telephone Number", "submissionValue": "CONPHONE", "synonyms": ["Contact Phone Number"]}, {"conceptId": "C176372", "definition": "Role of study contact.", "preferredTerm": "Study Contact Role", "submissionValue": "CONROLE", "synonyms": ["Contact Role"]}, {"conceptId": "C98715", "definition": "The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment.", "preferredTerm": "Confirmed Response Minimum Duration", "submissionValue": "CRMDUR", "synonyms": ["Confirmed Response Minimum Duration"]}, {"conceptId": "C139273", "definition": "The date when the clinical study report was archived.", "preferredTerm": "Clinical Study Report Archive Date", "submissionValue": "CSRARDTC", "synonyms": ["Clinical Study Report Archive Date"]}, {"conceptId": "C156602", "definition": "The name and version of the CDISC therapeutic area user guide that is being used in the study submission.", "preferredTerm": "CDISC Therapeutic Area User Guide Name and Version", "submissionValue": "CTAUG", "synonyms": ["CDISC Therapeutic Area User Guide"]}, {"conceptId": "C85582", "definition": "The literal identifier of the therapy or medication that is currently being given per protocol.", "preferredTerm": "Current Therapy", "submissionValue": "CURTRT", "synonyms": ["Current Therapy or Treatment"]}, {"conceptId": "C98718", "definition": "Text that describes the cutoff date.", "preferredTerm": "Data Cutoff Date Description", "submissionValue": "DCUTDESC", "synonyms": ["Data Cutoff Description"]}, {"conceptId": "C98717", "definition": "A date which indicates any data collected by this date will be used for analysis.", "preferredTerm": "Data Cutoff Date", "submissionValue": "DCUTDTC", "synonyms": ["Data Cutoff Date"]}, {"conceptId": "C135514", "definition": "A standard by which the determination of delayed graft function (DGF) is established.", "preferredTerm": "Delayed Graft Function Diagnostic Criteria Name", "submissionValue": "DGFCRIT", "synonyms": ["Delayed Graft Function Diagnostic Criteria", "Delayed Graft Function Dx Criteria"]}, {"conceptId": "C127790", "definition": "An indication as to whether the clinical trial has an appointed data monitoring committee.", "preferredTerm": "Data Monitoring Committee Indicator", "submissionValue": "DMCIND", "synonyms": ["Data Monitoring Committee Indicator"]}, {"conceptId": "C25488", "definition": "The amount of study drug (or placebo) administered to a patient or test subject to be taken at one time or at stated intervals.", "preferredTerm": "Dose", "submissionValue": "DOSE", "synonyms": ["Dose Level", "Dose per Administration"]}, {"conceptId": "C42636", "definition": "The physical form in which active and/or inert ingredient(s) are presented.", "preferredTerm": "Pharmaceutical Dosage Form", "submissionValue": "DOSFRM", "synonyms": ["Dose Form"]}, {"conceptId": "C89081", "definition": "The number of doses administered per a specific interval.", "preferredTerm": "Dose Frequency", "submissionValue": "DOSFRQ", "synonyms": ["Dosing Frequency"]}, {"conceptId": "C71137", "definition": "The planned schedule for the administration of an agent (such as a drug, substance or radiation).", "preferredTerm": "Dose Regimen", "submissionValue": "DOSRGM", "synonyms": ["Dose Regimen"]}, {"conceptId": "C73558", "definition": "The unit of measure for the dosage form.", "preferredTerm": "Dosage Form Unit", "submissionValue": "DOSU", "synonyms": ["Dose Units"]}, {"conceptId": "C117960", "definition": "A standard from which a judgment concerning a medical diagnosis can be established.", "preferredTerm": "Diagnostic Criteria", "submissionValue": "DXCRIT", "synonyms": ["Diagnostic Criteria"]}, {"conceptId": "C119560", "definition": "Indicates whether assessors of ECGs for this study were blinded to subject identity, timing and treatment.", "preferredTerm": "ECG Evaluator Blinding Parameters", "submissionValue": "EGBLIND", "synonyms": ["ECG Reading Blinded"]}, {"conceptId": "C119561", "definition": "Indicates whether the 10-second ECGs for this study were extracted from a continuous recording.", "preferredTerm": "ECG Continuous Monitoring Indicator", "submissionValue": "EGCTMON", "synonyms": ["ECG Continuous Monitoring"]}, {"conceptId": "C119562", "definition": "The ECG lead which was planned to be used for ECG interval measurements for this study.", "preferredTerm": "ECG Planned Primary Lead for Study", "submissionValue": "EGLEADPR", "synonyms": ["ECG Planned Primary Lead"]}, {"conceptId": "C119563", "definition": "Indicates whether all ECG interval measurements for the study were based on the same lead.", "preferredTerm": "ECG Used Same Lead Indicator", "submissionValue": "EGLEADSM", "synonyms": ["ECG Used Same Lead"]}, {"conceptId": "C119564", "definition": "The degree of automation involved in assessing the ECGs for this study.", "preferredTerm": "ECG Read Method Degree of Automation", "submissionValue": "EGRDMETH", "synonyms": ["ECG Read Method"]}, {"conceptId": "C119565", "definition": "Indicates whether this study includes replicate ECGs for time points during the baseline portion of the study.", "preferredTerm": "ECG Replicates at Baseline Indicator", "submissionValue": "EGREPLBL", "synonyms": ["ECG Replicates at Baseline"]}, {"conceptId": "C119566", "definition": "Indicates whether this study includes replicate ECGs for time points during the on-treatment portion of the study.", "preferredTerm": "ECG Replicates On-Treatment Indicator", "submissionValue": "EGREPLTR", "synonyms": ["ECG Replicates On-Treatment"]}, {"conceptId": "C119582", "definition": "The algorithm used to identify the end of the T wave for ECGs for this study.", "preferredTerm": "ECG T Wave Algorithm", "submissionValue": "EGTWVALG", "synonyms": ["ECG Twave Algorithm"]}, {"conceptId": "C127791", "definition": "The Email address to which copies of the XML format of the EudraCT application should be sent.", "preferredTerm": "E-mail Address for XML File Feedback", "submissionValue": "EMAILXML", "synonyms": ["Email Address for XML File"]}, {"conceptId": "C126059", "definition": "An alphanumeric code assigned by the European Medicines Agency (EMA) to an EMA regulatory decision for a pediatric investigation plan (PIP).", "preferredTerm": "EMA Decision Number for Pediatric Investigation Plan", "submissionValue": "EMPIPDCN", "synonyms": ["EMA Decision Number for PIP"]}, {"conceptId": "C171505", "definition": "An indication as to whether the study disruption was caused by the epidemic or pandemic.", "preferredTerm": "Epidemic or Pandemic Related Disruption Indicator", "submissionValue": "EPDISIND", "synonyms": ["Epi/Pandemic Related Disruption Ind", "Epidemic Related Disruption Indicator"]}, {"conceptId": "C171506", "definition": "The literal identifier of the epidemic and/or pandemic.", "preferredTerm": "Name of Epidemic or Pandemic", "submissionValue": "EPIDEMIC", "synonyms": ["Name of Epi/Pandemic", "Name of Epidemic and/or Pandemic"]}, {"conceptId": "C126060", "definition": "An indication as to whether the trial being submitted to the EudraCT is a trial that has been previously submitted to the EudraCT system.", "preferredTerm": "EudraCT Resubmission Indicator", "submissionValue": "EURSBIND", "synonyms": ["EudraCT Resubmission Indicator"]}, {"conceptId": "C126061", "definition": "A unique identifier assigned to the organization that is transmitting an adverse drug reaction report to the EudraVigilance system.", "preferredTerm": "EudraVigilance Sender Identifier", "submissionValue": "EVSNDID", "synonyms": ["EudraVigilance Sender ID"]}, {"conceptId": "C126090", "definition": "The name of the group or institution that is transmitting an adverse drug reaction report to the EudraVigilance system.", "preferredTerm": "EudraVigilance Sender Organization", "submissionValue": "EVSNDORG", "synonyms": ["EudraVigilance Sender Organization"]}, {"conceptId": "C127792", "definition": "The unique alphanumeric identifier for the study with associated expanded access record, as assigned by the clinicaltrials.gov protocol registration and results system (PRS).", "preferredTerm": "Clinicaltrials.gov NCT Number for the Expanded Access Record", "submissionValue": "EXPARECN", "synonyms": ["Expanded Access Record NCT Number"]}, {"conceptId": "C127793", "definition": "Status indicating availability of an experimental drug or device outside any clinical trial protocol. (clinicaltrials.gov)", "preferredTerm": "Trial Expanded Access Status", "submissionValue": "EXPASTAT", "synonyms": ["Expanded Access Status"]}, {"conceptId": "C139274", "definition": "An indication as to whether the clinical trial is an extension trial.", "preferredTerm": "Extension Trial Indicator", "submissionValue": "EXTTIND", "synonyms": ["Extension Trial Indicator"]}, {"conceptId": "C98770", "definition": "The country name of planned study facility which has received IRB approval.", "preferredTerm": "Planned Country of Investigational Site", "submissionValue": "FCNTRY", "synonyms": ["Planned Country of Investigational Sites"]}, {"conceptId": "C123629", "definition": "An indication as to whether the study involves an FDA-regulated device.", "preferredTerm": "FDA-Regulated Device Study Indicator", "submissionValue": "FDADEIND", "synonyms": ["FDA-Regulated Device Study Indicator"]}, {"conceptId": "C123630", "definition": "An indication as to whether the study involves an FDA-regulated drug.", "preferredTerm": "FDA-Regulated Drug Study Indicator", "submissionValue": "FDADRIND", "synonyms": ["FDA-Regulated Drug Study Indicator"]}, {"conceptId": "C156603", "definition": "The name and version of the FDA technical specification that is being used in the study submission.", "preferredTerm": "FDA Technical Specification Name and Version", "submissionValue": "FDATCHSP", "synonyms": ["FDA Technical Specification"]}, {"conceptId": "C98737", "definition": "Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study.", "preferredTerm": "Healthy Subject Indicator", "submissionValue": "HLTSUBJI", "synonyms": ["Healthy Subject Indicator"]}, {"conceptId": "C112038", "definition": "The textual representation of the condition, disease or disorder that the clinical trial is intended to investigate or address.", "preferredTerm": "Trial Indication", "submissionValue": "INDIC", "synonyms": ["Trial Disease/Condition Indication", "Trial Disease/Condition Indication Description"]}, {"conceptId": "C98746", "definition": "The general design of the strategy for assigning interventions to participants in a clinical study. (clinicaltrials.gov)", "preferredTerm": "Intervention Model", "submissionValue": "INTMODEL", "synonyms": ["Intervention Model"]}, {"conceptId": "C98747", "definition": "The kind of product or procedure studied in a trial.", "preferredTerm": "Intervention Type", "submissionValue": "INTTYPE", "synonyms": ["Intervention Type"]}, {"conceptId": "C126062", "definition": "A word or small set of words designed to convey the focus of the protocol.", "preferredTerm": "Protocol Keyword", "submissionValue": "KEYWORD", "synonyms": ["Protocol Keyword"]}, {"conceptId": "C49697", "definition": "Planned length of observation for a single subject.", "preferredTerm": "Trial Length", "submissionValue": "LENGTH", "synonyms": ["Trial Length"]}, {"conceptId": "C124455", "definition": "The name of the country within which the final product under study is produced.", "preferredTerm": "Country of Manufacture", "submissionValue": "MNFCNTRY", "synonyms": ["Country of Manufacture"]}, {"conceptId": "C127794", "definition": "An indication as to whether the clinical study is being conducted at multiple sites within the European Union member state concerned by the application.", "preferredTerm": "Multiple Site European Union State Trial Indicator", "submissionValue": "MSEUTIND", "synonyms": ["Multiple Site EU State Trial Indicator"]}, {"conceptId": "C98771", "definition": "The planned number of intervention groups.", "preferredTerm": "Planned Number of Arms", "submissionValue": "NARMS", "synonyms": ["Planned Number of Arms"]}, {"conceptId": "C126063", "definition": "The number of groups or cohorts that are part of the study.", "preferredTerm": "Number of Groups or Cohorts", "submissionValue": "NCOHORT", "synonyms": ["Number of Groups/Cohorts"]}, {"conceptId": "C127795", "definition": "The total number of trial sites within the European Union member state concerned by the application.", "preferredTerm": "Number of Trial Sites within European Union State", "submissionValue": "NUMSEUST", "synonyms": ["Number of Trial Sites EU State"]}, {"conceptId": "C163559", "definition": "The exploratory purpose of the trial.", "preferredTerm": "Trial Exploratory Objective", "submissionValue": "OBJEXP", "synonyms": ["Trial Exploratory Objective"]}, {"conceptId": "C85826", "definition": "A principle objective of the study.", "preferredTerm": "Trial Primary Objective", "submissionValue": "OBJPRIM", "synonyms": ["Study Primary Objective", "Trial Primary Objective"]}, {"conceptId": "C85827", "definition": "An auxiliary objective of the study.", "preferredTerm": "Trial Secondary Objective", "submissionValue": "OBJSEC", "synonyms": ["Study Secondary Objective", "Trial Secondary Objective"]}, {"conceptId": "C126064", "definition": "The trial design developed to compare biomedical and/or health outcomes in pre-defined and non-assigned groups of individuals.", "preferredTerm": "Observational Model", "submissionValue": "OBSMODEL", "synonyms": ["Observational Model"]}, {"conceptId": "C126065", "definition": "The temporal relationship between the observation period and time of subject enrollment. (ClinicalTrials.gov)", "preferredTerm": "Observational Time Perspective of Study", "submissionValue": "OBSTIMP", "synonyms": ["Observational Time Perspective"]}, {"conceptId": "C126066", "definition": "A description of the population from which the groups or cohorts will be selected within an observational study.", "preferredTerm": "Observational Study Population Description", "submissionValue": "OBSTPOPD", "synonyms": ["Obs Study Population Description"]}, {"conceptId": "C126067", "definition": "The sampling method used to assign study participants into groups or cohorts within an observational study.", "preferredTerm": "Observational Study Sampling Method", "submissionValue": "OBSTSMM", "synonyms": ["Observational Study Sampling Method"]}, {"conceptId": "C126068", "definition": "A textual description of the sampling method used to assign study participants into groups or cohorts within an observational study.", "preferredTerm": "Observational Study Sampling Method Description", "submissionValue": "OBSTSMMD", "synonyms": ["Obs Study Sampling Method Description"]}, {"conceptId": "C156601", "definition": "Additional key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures not used to assess primary or secondary objectives.", "preferredTerm": "Additional Outcome Measure", "submissionValue": "OUTMSADD", "synonyms": ["Additional Outcome Measure"]}, {"conceptId": "C98724", "definition": "The outcome measure(s) that is part of a pre-specified analysis plan used to evaluate the exploratory endpoint(s) associated with exploratory study objective(s) and/or any other measures, excluding post-hoc measures, that are a focus of the study. (After clinicaltrials.gov)", "preferredTerm": "Exploratory Outcome Measure", "submissionValue": "OUTMSEXP", "synonyms": ["Exploratory Outcome Measure"]}, {"conceptId": "C98772", "definition": "The outcome measure(s) of greatest importance specified in the protocol, usually the one(s) used in the power calculation, to evaluate the primary endpoint(s) associated with the primary study objective(s). (After Clinicaltrials.gov)", "preferredTerm": "Primary Outcome Measure", "submissionValue": "OUTMSPRI", "synonyms": ["Primary Outcome Measure"]}, {"conceptId": "C98781", "definition": "The outcome measure(s) that is part of a pre-specified analysis plan used to evaluate the secondary endpoint(s) associated with secondary study objective(s) and/or used to evaluate any measure(s) ancillary to the primary or secondary endpoint(s). (After Clinicaltrials.gov).", "preferredTerm": "Secondary Outcome Measure", "submissionValue": "OUTMSSEC", "synonyms": ["Secondary Outcome Measure"]}, {"conceptId": "C139275", "definition": "An indication as to whether the clinical study is a post authorization safety study.", "preferredTerm": "Post Authorization Safety Study Indicator", "submissionValue": "PASSIND", "synonyms": ["Post Authorization Safety Study Ind"]}, {"conceptId": "C98768", "definition": "The pharmacological class of the investigational product.", "preferredTerm": "Pharmacological Class of Investigational Therapy", "submissionValue": "PCLAS", "synonyms": ["Pharmacologic Class"]}, {"conceptId": "C123631", "definition": "An indication as to whether the study is a pediatric postmarket study.", "preferredTerm": "Pediatric Postmarket Study Indicator", "submissionValue": "PDPSTIND", "synonyms": ["Pediatric Postmarket Study Indicator"]}, {"conceptId": "C123632", "definition": "An indication as to whether the study is a pediatric study.", "preferredTerm": "Pediatric Study Indicator", "submissionValue": "PDSTIND", "synonyms": ["Pediatric Study Indicator"]}, {"conceptId": "C126069", "definition": "An indication as to whether the trial is part of a pediatric investigation plan (PIP).", "preferredTerm": "Pediatric Investigation Plan Indicator", "submissionValue": "PIPIND", "synonyms": ["Pediatric Investigation Plan Indicator"]}, {"conceptId": "C49692", "definition": "The planned number of subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Subject Number", "submissionValue": "PLANSUB", "synonyms": ["Anticipated Enrollment", "Planned Enrollment", "Planned Number of Subjects", "Target Enrollment"]}, {"conceptId": "C127796", "definition": "The approximate period of time over which the clinical trial is expected to occur.", "preferredTerm": "Planned Trial Duration", "submissionValue": "PLNTRDUR", "synonyms": ["Planned Trial Duration"]}, {"conceptId": "C139277", "definition": "The potential future harm that may arise from a protocol-related activity.", "preferredTerm": "Protocol Risk Assessment", "submissionValue": "PROTRSK", "synonyms": ["Protocol Risk Assessment"]}, {"conceptId": "C139276", "definition": "The period of time during which the treatment is intended to be given.", "preferredTerm": "Planned Treatment Duration", "submissionValue": "PTRTDUR", "synonyms": ["Planned Treatment Duration"]}, {"conceptId": "C127797", "definition": "A globally unique identifier for a biomedical article, as assigned by PubMed.", "preferredTerm": "PubMed Unique Identifier", "submissionValue": "PUBMEDID", "synonyms": ["PubMed ID for Citation Used in Study"]}, {"conceptId": "C25196", "definition": "The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary)", "preferredTerm": "Randomization", "submissionValue": "RANDOM", "synonyms": ["Trial is Randomized"]}, {"conceptId": "C98775", "definition": "The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects.", "preferredTerm": "Randomization Quotient", "submissionValue": "RANDQT", "synonyms": ["Randomization Quotient"]}, {"conceptId": "C126070", "definition": "An indication as to whether the condition under study is considered a rare disease.", "preferredTerm": "Rare Disease Indicator", "submissionValue": "RDIND", "synonyms": ["Rare Disease Indicator"]}, {"conceptId": "C98714", "definition": "Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries.", "preferredTerm": "Clinical Trial Registry Identifier", "submissionValue": "REGID", "synonyms": ["Registry Identifier"]}, {"conceptId": "C126071", "definition": "An alphabetic character that describes the incremental order of trial resubmissions.", "preferredTerm": "Resubmission Letter", "submissionValue": "RESUBLTR", "synonyms": ["Resubmission Letter"]}, {"conceptId": "C117961", "definition": "A standard from which a judgment concerning a disease relapse can be established.", "preferredTerm": "Relapse Criteria", "submissionValue": "RLPSCRIT", "synonyms": ["Relapse Criteria"]}, {"conceptId": "C38114", "definition": "The pathway by which a substance is administered in order to reach the site of action in the body.", "preferredTerm": "Route of Administration", "submissionValue": "ROUTE", "synonyms": ["Route of Administration"]}, {"conceptId": "C126072", "definition": "A textual description of the specimen types that are retained as reserve samples.", "preferredTerm": "Retained Biospecimen Description", "submissionValue": "RTSPCDES", "synonyms": ["Retained Biospecimen Description"]}, {"conceptId": "C127798", "definition": "An indication as to whether the registrant would like to receive an XML copy of their study as saved on EudraCT.", "preferredTerm": "Study Saved as XML Indicator", "submissionValue": "RXMLCIND", "synonyms": ["Request for XML Copy of Study Indicator"]}, {"conceptId": "C98783", "definition": "The protocol specified minimum amount of time needed to meet the definition of stable disease.", "preferredTerm": "Stable Disease Minimum Duration", "submissionValue": "SDMDUR", "synonyms": ["Stable Disease Minimum Duration"]}, {"conceptId": "C156604", "definition": "The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission.", "preferredTerm": "Study Data Tabulation Model Implementation Guide Version", "submissionValue": "SDTIGVER", "synonyms": ["SDTM IG Version", "SDTM Implementation Guide Version", "SDTMIG Version"]}, {"conceptId": "C189317", "definition": "The version of the CDISC Study Data Tabulation Model implementation guide for medical devices that is being used in the study submission.", "preferredTerm": "SDTM Implementation Guide Medical Device Version", "submissionValue": "SDTMDVER", "synonyms": ["SDTM IG Medical Device Version", "SDTM Implementation Guide Medical Device Version", "SDTMIG Medical Device Version", "SDTMIG-MD Version"]}, {"conceptId": "C156605", "definition": "The version of the CDISC Study Data Tabulation Model that is being used in the study submission.", "preferredTerm": "Study Data Tabulation Model Version", "submissionValue": "SDTMVER", "synonyms": ["SDTM Version"]}, {"conceptId": "C127799", "definition": "An indication as to whether the XML copy of the EudraCT application requires secure E-mail delivery.", "preferredTerm": "Requires Secure Email Delivery of XML Indicator", "submissionValue": "SDXMLIND", "synonyms": ["Secure Delivery XML Required Indicator"]}, {"conceptId": "C90462", "definition": "The date on which the final data item for a clinical study was collected from the last study participant (that is, last subject, last visit, or as otherwise defined in the study protocol). (CDISC Glossary)", "preferredTerm": "Clinical Study End Date", "submissionValue": "SENDTC", "synonyms": ["Study End Date"]}, {"conceptId": "C117962", "definition": "A standard from which a judgment concerning the severity of an event, disease or condition can be established.", "preferredTerm": "Severity Criteria", "submissionValue": "SEVCRIT", "synonyms": ["Severity Criteria"]}, {"conceptId": "C49696", "definition": "The specific sex, either male, female, or mixed of the subject group being studied. (NCI)", "preferredTerm": "Sex of Study Group", "submissionValue": "SEXPOP", "synonyms": ["Sex of Participants"]}, {"conceptId": "C70793", "definition": "An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP]", "preferredTerm": "Clinical Study Sponsor", "submissionValue": "SPONSOR", "synonyms": ["Clinical Study Sponsor", "Sponsor", "Study Sponsor"]}, {"conceptId": "C135009", "definition": "The reference identifier by which the study is known to the sponsor. This may be different from the STUDYID if the data were collected under a different identifier (e.g., used in a situation where a contract facility performs the study and provides a final report).", "preferredTerm": "Sponsor Study Reference Identifier", "submissionValue": "SPREFID", "synonyms": ["Sponsor's Study Reference ID"]}, {"conceptId": "C126073", "definition": "An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to a EudraVigiliance clinical trial module (EVCTM).", "preferredTerm": "SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator", "submissionValue": "SREVIND", "synonyms": ["SUSAR Reporting to EVCTM Indicator"]}, {"conceptId": "C126074", "definition": "An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to national competent authorities (NCA).", "preferredTerm": "SUSAR Reporting to National Competent Authority Indicator", "submissionValue": "SRNCAIND", "synonyms": ["SUSAR Reporting to NCA Indicator"]}, {"conceptId": "C127800", "definition": "An indication as to whether the clinical study is being conducted at only one site within the European Union member state concerned by the application.", "preferredTerm": "Single Site European Union State Trial Indicator", "submissionValue": "SSEUTIND", "synonyms": ["Single Site EU State Trial Indicator"]}, {"conceptId": "C69208", "definition": "The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included.", "preferredTerm": "Study Start Date", "submissionValue": "SSTDTC", "synonyms": ["Study Start Date"]}, {"conceptId": "C126075", "definition": "A textual description of the substudy.", "preferredTerm": "Substudy Details", "submissionValue": "SSTDYDTL", "synonyms": ["Substudy Details"]}, {"conceptId": "C126076", "definition": "An indication as to whether a study performed on a subgroup of subjects included in the original trial (substudy) is planned for the current study.", "preferredTerm": "Substudy Planned Indicator", "submissionValue": "SSTDYIND", "synonyms": ["Substudy Planned Indicator"]}, {"conceptId": "C49698", "definition": "The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI)", "preferredTerm": "Study Stop Rule", "submissionValue": "STOPRULE", "synonyms": ["Study Stop Rules"]}, {"conceptId": "C16153", "definition": "Selected factors that are used during randomization to ensure there is balance of these factors across all subjects within each arm of a study. The subject level values of these factors may be used as fixed effects in statistical models and for sensitivity analyses.", "preferredTerm": "Stratification Factors", "submissionValue": "STRATFCT", "synonyms": ["Stratification Factor"]}, {"conceptId": "C142175", "definition": "The nature of the investigation for which study information is being collected. (After clinicaltrials.gov)", "preferredTerm": "Study Type", "submissionValue": "STYPE", "synonyms": ["Study Type", "Study Type Classification"]}, {"conceptId": "C49658", "definition": "The type of experimental design used to describe the level of awareness of the study subjects and/ or study personnel as it relates to the respective intervention(s) or assessments being observed, received or administered.", "preferredTerm": "Trial Blinding Schema", "submissionValue": "TBLIND", "synonyms": ["Study Blinding Design", "Study Blinding Schema", "Study Masking Design", "Trial Blinding Design", "Trial Blinding Schema", "Trial Masking Design"]}, {"conceptId": "C49647", "definition": "Comparator against which the study treatment is evaluated.", "preferredTerm": "Control Type", "submissionValue": "TCNTRL", "synonyms": ["Control Type"]}, {"conceptId": "C49650", "definition": "A grouping of individuals on the basis of a shared procedure or disease, or lack thereof.", "preferredTerm": "Diagnosis Group", "submissionValue": "TDIGRP", "synonyms": ["Diagnosis Group"]}, {"conceptId": "C101302", "definition": "A categorization of a disease, disorder, or other condition based on common characteristics and often associated with a medical specialty focusing on research and development of specific therapeutic interventions for the purpose of treatment and prevention.", "preferredTerm": "Therapeutic Area", "submissionValue": "THERAREA", "synonyms": ["Therapeutic Area"]}, {"conceptId": "C49652", "definition": "The planned purpose of the therapy, device, or agent under study in the clinical trial.", "preferredTerm": "Clinical Study by Intent", "submissionValue": "TINDTP", "synonyms": ["Trial Intent Type"]}, {"conceptId": "C49802", "definition": "The sponsor-defined name of the clinical study.", "preferredTerm": "Trial Title", "submissionValue": "TITLE", "synonyms": ["Official Study Title", "Study Title", "Trial Title"]}, {"conceptId": "C48281", "definition": "A step in the clinical research and development of a therapy from initial clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]", "preferredTerm": "Trial Phase", "submissionValue": "TPHASE", "synonyms": ["Trial Phase", "Trial Phase Classification"]}, {"conceptId": "C126077", "definition": "The anticipated time period over which each study participant is to be followed. (ClinicalTrials.gov)", "preferredTerm": "Planned Follow-Up Duration", "submissionValue": "TRGFUDUR", "synonyms": ["Target Follow-Up Duration"]}, {"conceptId": "C41161", "definition": "The investigational product under study.", "preferredTerm": "Protocol Agent", "submissionValue": "TRT", "synonyms": ["Investigational Therapy or Treatment"]}, {"conceptId": "C49660", "definition": "The nature of the interventional study for which information is being collected.", "preferredTerm": "Trial Type", "submissionValue": "TTYPE", "synonyms": ["Trial Scope", "Trial Type"]}, {"conceptId": "C127801", "definition": "The uniform resource locator (URL) related to a particular study.", "preferredTerm": "Study Protocol Uniform Resource Locator", "submissionValue": "URLSTDY", "synonyms": ["URL Related to Study"]}, {"conceptId": "C127802", "definition": "A textual description of the uniform resource locator (URL) related to a particular study.", "preferredTerm": "Study Protocol Uniform Resource Locator Description", "submissionValue": "URLSTDYD", "synonyms": ["URL Related to Study Description"]}]}